tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CLYM Stock Latest News

Climb Bio’s Promising ITP Study: A Potential Game-Changer for Investors
Company AnnouncementsClimb Bio’s Promising ITP Study: A Potential Game-Changer for Investors
9d ago
CLYM
Climb Bio’s Promising Phase 1b Study on Budoprutug for Lupus: A Market Game-Changer?
PremiumCompany Announcements
Climb Bio’s Promising Phase 1b Study on Budoprutug for Lupus: A Market Game-Changer?
9d ago
CLYM
Climb Bio’s Phase 2 Study on Budoprutug: A Potential Game-Changer in Nephrology
PremiumCompany Announcements
Climb Bio’s Phase 2 Study on Budoprutug: A Potential Game-Changer in Nephrology
9d ago
CLYM
Climb Bio’s Budoprutug Study: A Promising Step Forward
PremiumCompany Announcements
Climb Bio’s Budoprutug Study: A Promising Step Forward
9d ago
CLYM
Climb Bio appoints Adam Villa as SVP, technical operations
PremiumThe Fly
Climb Bio appoints Adam Villa as SVP, technical operations
15d ago
CLYM
Climb Bio Releases New Clinical Data on Budoprutug
PremiumCompany AnnouncementsClimb Bio Releases New Clinical Data on Budoprutug
19d ago
8K
CLYM
Climb Bio presents preclinical data on CLYM116 at ASN Kideny Week
Premium
The Fly
Climb Bio presents preclinical data on CLYM116 at ASN Kideny Week
19d ago
CLYM
Climb Bio initiated with an Outperform at William Blair
Premium
The Fly
Climb Bio initiated with an Outperform at William Blair
20d ago
CLYM
Climb Bio initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Climb Bio initiated with a Buy at H.C. Wainwright
23d ago
CLYM
Climb Bio management to meet virtually with BTIG
PremiumThe Fly
Climb Bio management to meet virtually with BTIG
30d ago
CLYM
Climb Bio Appoints New CFO Susan Altschuller
PremiumCompany Announcements
Climb Bio Appoints New CFO Susan Altschuller
1M ago
8K
CLYM
Climb Bio appoints Altschuller as Chief Financial Officer
PremiumThe Fly
Climb Bio appoints Altschuller as Chief Financial Officer
1M ago
ABBV
CLYM
Climb Bio price target raised to $8 from $7 at BTIG
PremiumThe FlyClimb Bio price target raised to $8 from $7 at BTIG
1M ago
CLYM
Climb Bio Unveils Promising Preclinical Data for CLYM116
Premium
Company Announcements
Climb Bio Unveils Promising Preclinical Data for CLYM116
1M ago
8K
CLYM
Climb Bio announces CLYM116 preclinical data
Premium
The Fly
Climb Bio announces CLYM116 preclinical data
1M ago
CLYM
Climb Bio to host webcast highlighting CLYM116, IgA Nephropathy opportunity
PremiumThe Fly
Climb Bio to host webcast highlighting CLYM116, IgA Nephropathy opportunity
2M ago
CLYM
Climb Bio: Strong Clinical Execution and Promising Pipeline Make It a Compelling Investment Opportunity
PremiumRatings
Climb Bio: Strong Clinical Execution and Promising Pipeline Make It a Compelling Investment Opportunity
3M ago
CLYM
Climb Bio initiated with an Outperform at Baird on budoprutug potential
PremiumThe Fly
Climb Bio initiated with an Outperform at Baird on budoprutug potential
3M ago
CLYM
Climb Bio initiated with an Outperform at Baird
PremiumThe Fly
Climb Bio initiated with an Outperform at Baird
3M ago
CLYM
Climb Bio Reports Progress in Clinical Trials and Financial Stability
PremiumCompany AnnouncementsClimb Bio Reports Progress in Clinical Trials and Financial Stability
3M ago
CLYM
Climb Bio reports Q2 EPS (13c) vs ($1.81) last year
Premium
The Fly
Climb Bio reports Q2 EPS (13c) vs ($1.81) last year
3M ago
CLYM
Oppenheimer Predicts Up to 590% Rally for These 2 ‘Strong Buy’ Stocks
Premium
Market News
Oppenheimer Predicts Up to 590% Rally for These 2 ‘Strong Buy’ Stocks
3M ago
WVE
CLYM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >